AACR Annual Meeting 2025, Chicago, IL, April 25-30

‍

genOway’s program at the American Association for Cancer Research Annual Meeting 2025

‍

Save your spot for one of our activities!

‍

🤝 Book a 1:1 with our team of scientific experts

April 27-30, 2025 - BOOTH #645

We will be happy to discuss your needs on:

• Ready-to-use catalogue models in oncology
• Creation of custom-made models
• Preclinical support solutions and proof-of-concept studies

⮞ Book your 1:1, fill in the form below (make sure to indicate your preferred time and date in your message)

‍

🔬 Join our Spotlight Theater presentation

Tuesday, April 29, 2025 | 3 pm - Spotlight Theater E

Title: "Assessment of translational tumor biology, and biologic's efficacy and safety in preclinical humanized models"‍

Abstract: Humanized models often lack accuracy and translatability regarding TME composition and tumor plasticity. This talk will present a humanized model in which human immune cell recruitment and activation in the TME is dependent on tumor type and burden. The presence of human myeloid and lymphoid cells allows assessment of the efficacy and safety of immunotherapies designed to reprogram TME composition. Alternatively, the assessment of therapies such as ADC and those inducing ADCC could be studied in a model expressing humanized FcγR, which, in contrast to humanized mice, shows a fully functional crosstalk between tumor, immune and stromal cells.

‍⮞ To save your seat for the presentation, fill in the form below

‍

📰 Attend our poster presentations

‍📅 April 28, 2025, 2:00 PM - 5:00 PM
⮞ #3126: Tumor cell line-derived xenograft subtype shapes tumor microenvironment composition in genO-BRGSF-HIS mice
⮞ #3230: Preclinical double-humanized genO-hCD47/hSIRPα mouse model and MC38 cell line expressing human CD47 for efficacy and safety assessment of anti-CD47/SIRPα-targeting therapies

‍📅 April 29, 2025, 2:00 PM - 5:00 PM
⮞ #5244: Assessment of γδT-cell therapies in genO-BRGSF-HIS mice

‍📅 April 30, 2025, 9:00 AM - 12:00 PM
⮞ #7273: genO-hCCR8/hCCL1 humanized model for efficacy assessment of CCR8/CCL1-targeting therapies

‍

You can access more detailed information about the AACR 2025 here